184 related articles for article (PubMed ID: 37318861)
21. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
[TBL] [Abstract][Full Text] [Related]
22. Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma.
Yang G; Yue H; Zhang X; Zeng C; Tan L; Zhang X
Front Immunol; 2024; 15():1336798. PubMed ID: 38779667
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemoradiotherapy, chemotherapy, and radiotherapy do not significantly increase the incidence of anastomotic leakage after esophageal cancer surgery: a meta-analysis.
Jin Z; Zhang J; Chen D; Wu S; Xue P; Zhu K; Xu C; Zhu C; Zhang B
Dis Esophagus; 2022 Sep; 35(9):. PubMed ID: 34952537
[TBL] [Abstract][Full Text] [Related]
24. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Pucher PH; Rahman SA; Walker RC; Grace BL; Bateman A; Iveson T; Jackson A; Rees C; Byrne JP; Kelly JJ; Noble F; Underwood TJ
Eur J Surg Oncol; 2020 Dec; 46(12):2248-2256. PubMed ID: 32694054
[TBL] [Abstract][Full Text] [Related]
25. Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma.
Cheng J; Guo M; Yang Y; Liu Y; Hu W; Shang Q; Li C; Xia L; Wang Y; Wang W; Tian D; Yuan Y; Hu Y; Chen L
Front Immunol; 2022; 13():848881. PubMed ID: 35371089
[TBL] [Abstract][Full Text] [Related]
26. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
[TBL] [Abstract][Full Text] [Related]
27. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Xu J; Cai Y; Hong Z; Duan H; Ke S
Int J Surg; 2024 Jan; 110(1):490-506. PubMed ID: 37800587
[TBL] [Abstract][Full Text] [Related]
28. Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
Hong ZN; Huang Z; Weng K; Lin J; Kang M
Front Immunol; 2022; 13():1036396. PubMed ID: 36311738
[TBL] [Abstract][Full Text] [Related]
29. Concurrent radiotherapy cannot provide superiority of surgical oncological outcome and long-term survival rate in locally advanced esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy followed by minimally invasive esophagectomy.
Wang YJ; Bao T; Li KK; Xie XF; He XD; Zhao XL; Guo W
Surg Endosc; 2023 Sep; 37(9):7073-7082. PubMed ID: 37380741
[TBL] [Abstract][Full Text] [Related]
30. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
[TBL] [Abstract][Full Text] [Related]
32. Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers.
Matsuda S; Kitagawa Y; Okui J; Okamura A; Kawakubo H; Takemura R; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
Esophagus; 2023 Jul; 20(3):445-454. PubMed ID: 36662353
[TBL] [Abstract][Full Text] [Related]
33. A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Front Immunol; 2023; 14():1217967. PubMed ID: 37954582
[TBL] [Abstract][Full Text] [Related]
34. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
Gao L; Hong ZN; Wu L; Yang Y; Kang M
Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of geriatric nutritional risk index in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Eur J Surg Oncol; 2024 Jun; 50(6):108323. PubMed ID: 38603867
[TBL] [Abstract][Full Text] [Related]
36. Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell carcinoma post-surgery.
Li C; Yu P; Li H; Yang X; Wang J; Jiang B
J Cardiothorac Surg; 2024 Jan; 19(1):26. PubMed ID: 38273405
[TBL] [Abstract][Full Text] [Related]
37. [Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer].
Sun R; Cong L; Qiu HZ; Lin GL; Wu B; Niu BZ; Sun XY; Zhou JL; Xu L; Lu JY; Xiao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):522-530. PubMed ID: 35754217
[No Abstract] [Full Text] [Related]
38. Anastomotic complications after esophagectomy: Influence of omentoplasty in propensity-weighted cohorts.
Lu M; Luketich JD; Levy RM; Awais O; Sarkaria I; Visintainer P; Nason KS
J Thorac Cardiovasc Surg; 2020 May; 159(5):2096-2105. PubMed ID: 31932061
[TBL] [Abstract][Full Text] [Related]
39. Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study.
Gronnier C; Tréchot B; Duhamel A; Mabrut JY; Bail JP; Carrere N; Lefevre JH; Brigand C; Vaillant JC; Adham M; Msika S; Demartines N; El Nakadi I; Piessen G; Meunier B; Collet D; Mariette C; ; Luc G; Cabau M; Jougon J; Badic B; Lozach P; Cappeliez S; Lebreton G; Alves A; Flamein R; Pezet D; Pipitone F; Iuga BS; Contival N; Pappalardo E; Mantziari S; Hec F; Vanderbeken M; Tessier W; Briez N; Fredon F; Gainant A; Mathonnet M; Bigourdan JM; Mezoughi S; Ducerf C; Baulieux J; Pasquer A; Baraket O; Poncet G; Vaudoyer D; Enfer J; Villeneuve L; Glehen O; Coste T; Fabre JM; Marchal F; Frisoni R; Ayav A; Brunaud L; Bresler L; Cohen C; Aze O; Venissac N; Pop D; Mouroux J; Donici I; Prudhomme M; Felli E; Lisunfui S; Seman M; Petit GG; Karoui M; Tresallet C; Ménégaux F; Hannoun L; Malgras B; Lantuas D; Pautrat K; Pocard M; Valleur P
Ann Surg; 2014 Nov; 260(5):764-70; discussion 770-1. PubMed ID: 25379847
[TBL] [Abstract][Full Text] [Related]
40. Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores.
Feng J; Wang L; Yang X; Chen Q; Cheng X
J Inflamm Res; 2022; 15():3783-3796. PubMed ID: 35832830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
